Coherus Oncology, Inc. (CHRS) bonds
CHRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/3059% below fair value
$0.48−0.03 (-5.42%)
Close on Nov 17, 2026Market cap $73.93MP/E –Yield –
Debt
Borrowings on the balance sheet, Jun 30, 2026
Coherus Oncology reports no long-term debt line
Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.
Notes and loans outstanding
As tagged in Coherus Oncology's 10-K for the period ended Dec 31, 2025
| Issue | Coupon | Amount issued | Carrying value |
|---|---|---|---|
| 2027 Term Loans | Floating + 1.00% | $250.00M | – |
| 2029 Term Loans | – | – | $54.42M |
Companies tag their debt differently: some list every note, others group notes by issuance year or by type, so the list may not add up to total debt. Notes that matured before today are hidden. Source: 10-K.
See a number that looks wrong?